In conclusion, we showed that the effect of ticagrelor related to the mitigation of endothelial dysfunction in stable CAD/COPD patients may be mediated, at least in part, by its capacity to increase SIRT1 and HES1 mRNAs levels (Supplementary Figure S1). This evidence concerns the gene HES1 and coronary artery disorder.